Nootropic drugs in the treatment of alzheimer’s disease_ cerebrolysin

As we reported in the first of this series on Alzheimer’s disease, nootropic drugs exert a regulatory effect on neuronal metabolism, and influence synaptic plasticity and learning behavior. Dementia and alzheimer’s disease Some research investigators saw a use of this class of drugs in treating Alzheimer’s disease. How long can you live with alzheimer’s disease The difficulty in using these drugs was how to deliver them so that they would pass through the blood-brain barrier, a membranous barrier that segregates the brain interstitial fluid surrounding the synapses from the circulating blood.

What causes alzheimer disease 2013 Once in the fluid, they could exert an effect on the synapses. Alzheimer’s disease medications This difficulty has been solved and now the race is on to develop a drug that could prove effective in treating Alzheimer’s disease and possibly have some protective effect to shield against Alzheimer’s disease.

Cerebrolysin is a nootropic drug that has been shown to have a neurotrophic effect inside the brain through its biologically active peptides. Treatment for alzheimer’s disease Ruther and his group, reporting in the journal Pharmacopsychiatry in 1994 on the “Efficacy of the peptidergic nootropic drug Cerebrolysin” in patients with senile dementia of the Alzheimer’s disease type” suggested that a sustained improvement in the treatment group was recorded 6 months after the start of drug therapy”. Early signs of alzheimer disease may include This implies that the progression of the disease was slowed in the Cerebrolysin group.

This month, a group of Korean investigators, reporting in the Journal of the American Geriatric Society (JAGS) suggested that “the peripheral application of Cerebrolysin protected cholinergic cells in the medial system from degeneration” after only 4 weeks of therapy. The first stage of alzheimer disease is characterized by The subjects used in this research were 35 women and 18 men, with 34 of these individuals in the treatment group and 19 in a placebo group. 10 signs of alzheimer disease The study used a randomized, multicentered, double blind, placebo-controlled protocol. Physiological effects of alzheimer disease Participants in the study had mild to moderate Alzheimer’s disease. Alzheimer’s disease dementia They were treated in an inpatient setting with 3 ampoules (30 mL of Cerebrolysin) in 100mL physiological saline IV. First stage of alzheimer disease is characterized by The infusions were given for more than 30 minutes once a day from Monday to Friday for 4 weeks. Alzheimer disease smell test They report no adverse effects from the drug treatment as opposed to some of the other medications on the market today.

The sample studied in this research was small and involved an intravenous inpatient treatment protocol. Stages of alzheimer’s disease This treatment was geared toward alleviating the progressive symptoms, and is not a cure for Alzheimer’s disease. Alzheimer’s disease research center There is no report on the individual cost-effectiveness of this medication protocol. Alzheimer’s disease prevention A study like this will have to be repeated with a larger pool of individuals and will have to look at the results at 6months and one year when compared to a placebo group to determine its effectiveness. All about alzheimer’s disease We would also note a word of caution in using an IV treatment: it increases the potential for infection.

It seems now that almost every month brings another report of some medication that promises to repair damaged brains. Interesting facts about alzheimer’s disease Tantalizing reports give us hope. Alzheimer’s disease journal articles The above information on Cerebrolysin is one of those reports that people should know about, but understand it a palliative treatment. Physical effects of alzheimer’s disease The more exciting news is the work being done on stem cells that could mean easily accessible cells from bone marrow might someday be used to treat a wide range of neurological diseases. Treatment alzheimer’s disease Future articles in this series will contain information about research in this area.

Ruther E., Ritter R., Apecechea M. Effects of alzheimer’s disease et al. Alzheimer’s disease pathology Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer’s disease type. Alzheimer’s disease description Pharmacopsychiatry 1994; 27: 32-40

Bae CH, Cho CY, Cho K, Oh BH et al. Articles on alzheimer’s disease A Double Blind, Placebo-Controlled, Multicentered Study of Cerebrolysin for Alzheimer’s Disease. Is there a treatment for alzheimer’s disease JAGS 2001: 48:1566-1571.